Recent biotech developments demonstrate advanced modalities in gene and antibody therapies. Shape Therapeutics partnered with VectorY Therapeutics in a $1.2 billion deal leveraging a brain-penetrating AAV capsid technology for gene delivery to neurodegenerative targets. Alchemab received $32 million to progress neuroprotective antibody candidates and partnerships with Eli Lilly. Regeneron reported successful Phase 3 results for garetosmab in fibrodysplasia ossificans progressiva and showed promising updates on combination therapies for obesity. Meanwhile, MIT researchers engineered antibody-bottlebrush conjugates (ABCs) enabling higher payloads with reduced toxicity, exemplifying next-generation cancer therapies. These advances reflect the growing sophistication of molecularly targeted therapeutics across oncology and rare disease indications.